National audit on the management of bullous pemphigoid

• Published in: Clinical and experimental dermatology Vol. 45; no. 3; pp. 289 - 294
• Main Authors: Smith, H., Mohd Mustapa, M. F., Cheung, S. T., Berker, D. A. R.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.04.2020
• Subjects: Blood pressure; Bullous pemphigoid; Corticosteroids; Diabetes mellitus; Documentation; Geriatrics; Hemoglobin; Immunofluorescence; Osteoporosis; Patient satisfaction; Patients
• ISSN: 0307-6938; 1365-2230
• DOI: 10.1111/ced.14086

Summary Background Bullous pemphigoid (BP) is an autoimmune, subepidermal, blistering condition that typically affects elderly people. Aim To undertake a national clinical audit based on standards derived from the British Association of Dermatologists (BAD) clinical guidelines on the management of BP. Methods In 2018, BAD members were invited to submit data for five consecutive adults with BP per centre, who had been under hospital supervision for at least 12 months, in a national audit over an 11‐week period. Results In total, 123 responders from 120 hospitals provided data for 524 cases. Diagnosis was made either clinically (10.7%; 56 of 524) or through histology with direct immunofluorescence (41.6%; 218 of 524), indirect immunofluorescence (10.3%; 54 of 524) or both (37.4%; 196 of 524). Most patients had very mild baseline disease (63.9%; 225 of 352) with 21.9% (77 of 352) considered mild, 9.8% (31 of 352) moderate and 5.4% (19 of 352) severe. Documentation of diabetes, glycated haemoglobin (HbA1c), blood pressure and hypertension was available for 54.1% (283 of 523), 51% (267 of 524), 44.2% (231 of 522) and 61.5% (321 of 522) of cases, respectively. Oral corticosteroids were commenced in 85.5% (448 of 524) of patients, with 38.4% (172 of 448) of these having documented risk of osteoporosis; data regarding prescription of bone‐protection therapies were available for 99.7% (447 of 448) of cases, with 75.6% (338 of 447) of these having a bone‐protection prescription. Patient satisfaction was documented in 59.3% (310 of 523) of cases. Systemic treatment was commenced in 95.9% (502 of 524) of cases during the 12‐month assessment period, with baseline blood test and follow‐up data available for 96.6% (485 of 502) and 95.6% (480 of 502), respectively. Documentation of baseline blood tests was available for 87.4% (424 of 485) of cases, with follow‐up tests recorded in 69.8% (335 of 480). Conclusion Overall, compliance with elements of documentation was moderate or low, whereas standards pertaining to direct care were high.